Compare Summit Therapeutics Inc (SMMT) vs Union Pacific Corporation (UNP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Summit Therapeutics Inc vs Union Pacific Corporation — how do they compare? Summit Therapeutics Inc trades at $17.58 (market cap $13.98B), while Union Pacific Corporation trades at $286.67 (market cap $169.16B). The key difference: Union Pacific Corporation is far larger — about 12.1× Summit Therapeutics Inc's market cap, and Union Pacific Corporation pays a 1.99% dividend while Summit Therapeutics Inc pays none. Which is the better fit depends on your goals.
| SMMT | UNP | |
|---|---|---|
Market Cap | $13.98B | $169.16B |
Sector | Health | Industrials |
52-Week High | $26.38 | $310.62 |
52-Week Low | $12.43 | $214.91 |
Enterprise Value | $13.31B | $198.21B |
Dividend Yield | — | 1.99% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Summit Therapeutics (SMMT) trades at $17.28, down 1.85% on the day, with a bullish technical signal from moving averages but overbought RSI readings. The company reported a net loss of $1.08 billion for 2025, negative ROE of -192.5%, and relies on financing cash flow for liquidity. Recent news highlights positive Phase III trial results for ivonescimab in lung and biliary tract cancers, driving investor optimism ahead of a key FDA decision in November 2026.
The outlook hinges on regulatory approval and commercial success of ivonescimab, with a consensus price target of $25.23 implying 46% upside. Risks include high cash burn, clinical trial uncertainties, and potential dilution from financing activities. Analyst sentiment is bullish (60.9% buy ratings), but the stock remains speculative due to its pre-revenue status and dependence on pipeline milestones.
Union Pacific (UNP) trades at $288.45, down 0.4% with a bearish technical signal despite strong fundamentals. The company reported solid Q2 2026 earnings beat ($3.41 vs $3.26 expected) and maintains robust profitability with 28.85% net margin and 39.7% ROE. Recent news highlights progress on the Norfolk Southern merger, expected to close by late 2027, while institutional activity shows mixed positioning with some funds increasing stakes while others reduced exposure.
The stock offers upside to the $334.33 consensus price target with 58.7% analyst buy ratings, though technical resistance near $290-294 and merger regulatory risks warrant monitoring. Strong cash flow generation ($9.29B operating cash flow in 2025) and dividend payments ($1.42 declared for H2-26) support shareholder returns, while debt levels remain manageable at 46.06% debt-to-asset ratio.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Summit Therapeutics Inc
Summit Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of new medicines for the treatment of infectious diseases and other unmet medical needs. The company's lead product candidate is an antibiotic for the treatment of Clostridioides difficile infection (CDI), a serious infection of the colon. Summit Therapeutics is committed to bringing innovative therapies to market to address global health challenges and improve patient outcomes.
Read more on SMMT →About Union Pacific Corporation
Omaha, Nebraska-based Union Pacific is the largest public railroad in North America. Operating on more than 30,000 miles of track in the western two thirds of the U.S., UP generated roughly $22 billion of revenue in 2021 by hauling coal, industrial products, intermodal containers, agriculture goods, chemicals, and automotive goods. UP owns about one fourth of Mexican railroad Ferromex and derives about 10% of its revenue hauling freight to and from Mexico.
Read more on UNP →
